Expert Point of View: Busulfan/Melphalan Improves Survival in High-risk Neuroblastoma Patients, Phase III Study Results Show


Get Permission

Julie R. Park, MDAt the ASCO Plenary Session where the HR-NBL1/SIOPEN trial was presented, formal discussant Julie R. Park, MD, of the University of Washington, Seattle, said, “Large randomized trials have previously shown that myeloablative therapy improves outcomes in high-risk neuroblastoma, and it is now considered standard of care.”

Dr. Park explained that the COJEC regimen used in this study may have contributed to the lower-than-expected 3-year event-free survival in the CEM arm. Previous studies conducted by the Children’s Oncology Group achieved a 3-year event-free survival of 46% with CEM, but those studies used a different induction regimen with lower doses of cisplatin and etoposide and did not include carboplatin.

“It is possible that rapid COJEC had a negative interaction with CEM, but not BuMel,” she said.

“The SIOPEN trial is a great achievement and shows the unity of 20 European nations. This study confirms the importance of myeloablative therapy in a cohort of high-risk neuroblastoma with a good response,” Dr. Park stated. She said that improved induction regimens should be a focus of future research so that cure rates can be increased. ■

Financial Disclosure: Dr. Park reported no potential conflicts of interest.


Related Articles

Plenary Report: Bu/Mel Improves Survival in High-risk Neuroblastoma Patients, Phase III Study Shows

Ruth Ladenstein, MDMyeloablative therapy with a busulfan (Busulfex, Myleran)/melphalan combination (BuMel) was superior to a regimen of carboplatin/etoposide/melphalan (CEM) in pediatric patients with high-risk neuroblastoma, according to results of the large, phase III HR-NBL1/SIOPEN trial presented at the 2011 ASCO ...

Advertisement

Advertisement

Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.